Friday, September 24, 2021  | 16 Safar, 1443
Samaa TV
Facebook Twitter Youtube
HOME > Health

Pfizer-BioNTech begin COVID-19 vaccine trial in young children

Moderna and AstraZeneca are also trying their vaccines in children

SAMAA | - Posted: Mar 26, 2021 | Last Updated: 6 months ago
SAMAA |
Posted: Mar 26, 2021 | Last Updated: 6 months ago

Photo: AFP

Listen to the story
Pfizer said Thursday it had begun clinical trials for its Covid-19 vaccine in children under the age of eleven, an early sign of the next stage of the global immunization campaign. "Together with our partner BioNTech, we have dosed the first healthy children in a global Phase 1/2/3 continuous study to further evaluate the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine," the company said in a statement to AFP. "We are proud to start this much needed study for children and families eagerly awaiting a possible vaccine option." According to details posted on the site clinicaltrials.gov, the company is testing three different dosing levels for use in this age group.  The company is already testing the shots in children aged 12 to 15, and its US emergency authorization covers people aged 16 and up.  Pfizer joins Moderna and AstraZeneca in testing their vaccines in younger children, while Johnson & Johnson has plans to follow. While children are generally spared the worst of the disease and are less likely than adults to transmit the virus, rare cases of serious Covid and deaths do occur, as well as a post-infectious inflammatory condition called MIS-C. Under-18s account for roughly a fifth of the US population of 330 million, and most experts believe it will be necessary to make inroads towards immunizing children in order to achieve population level immunity.
FaceBook WhatsApp

Pfizer said Thursday it had begun clinical trials for its Covid-19 vaccine in children under the age of eleven, an early sign of the next stage of the global immunization campaign.

“Together with our partner BioNTech, we have dosed the first healthy children in a global Phase 1/2/3 continuous study to further evaluate the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine,” the company said in a statement to AFP.

“We are proud to start this much needed study for children and families eagerly awaiting a possible vaccine option.”

According to details posted on the site clinicaltrials.gov, the company is testing three different dosing levels for use in this age group. 

The company is already testing the shots in children aged 12 to 15, and its US emergency authorization covers people aged 16 and up. 

Pfizer joins Moderna and AstraZeneca in testing their vaccines in younger children, while Johnson & Johnson has plans to follow.

While children are generally spared the worst of the disease and are less likely than adults to transmit the virus, rare cases of serious Covid and deaths do occur, as well as a post-infectious inflammatory condition called MIS-C.

Under-18s account for roughly a fifth of the US population of 330 million, and most experts believe it will be necessary to make inroads towards immunizing children in order to achieve population level immunity.

 
HOME  
 
 
RELATED STORIES

Tell us what you think:

Your email address will not be published.

FaceBook WhatsApp
 
 
 
covid vaccine, pfizer vaccine, pfizer-biontech, coronavirus, COVID-19 vaccine, covid vaccine for children
 

MOST READ
MOST READ
Third monsoon spell hits Sindh, heavy rain in Karachi
Pay Orangi, Gujjar nullah victims: SC tells CM
Women must come forward to inherit during their lifetimes: SC
Light rain expected in Karachi today
 
 
 
 
 
About Us   |   Anchor Profiles   |   Online Advertising   |   Contact Us   |   Feedback   |   Apps   |   FAQs   |   Authors   |   Comment Policy
Facebook   |   Twitter   |   Instagram   |   YouTube   |   WhatsApp